In short, it is a personalization strategy, not a formally validated alternative to labeled dosing
Back Day, JW, Ottaway, N, Patterson, JT, et al (13 July 2009) 'A new glucagon and GLP-1 co-agonist eliminates obesity in rodents', Nature Chemical Biology
This short-term thinking makes it difficult to convince insurance companies to cover treatments like GLP-1 medications, even though they could reduce health care costs in the long run
The Legal Framework: Section 503A Section 503A of the Federal Food, Drug, and Cosmetic Act creates a regulated pathway for licensed pharmacies to compound prescription medications
Talk about goals and risks with your prescribing clinician to decide
Blood flow matters most